Amoéba: Positive Results of the 2025 Vine Trials

Amoéba has revealed the results of its 2025 vineyard trials, confirming the effectiveness of AXPERA against downy mildew, a particularly aggressive disease in recent years. With 15 demonstrations across France, in partnership with various stakeholders, the trials show efficacy similar to that of conventional treatments, while reducing copper use by up to 66%.

Faced with increasingly strict French regulations on copper-based products, AXPERA presents itself as a viable natural alternative. Already approved as a biofungicide in the United States, its commercialization in Europe is planned for 2026, with an extension to other crops envisioned as early as 2027.

Amoéba is considering a strategic partnership with Koppert to launch AXPERA in southern Europe. Projections anticipate a significant expansion of treated areas by 2032.